Loading viewer...
earnings
Format: PDF earnings
Vertex Pharmaceuticals presented its fourth quarter and full year 2022 financial results on February 7, 2023, highlighting pipeline progress across cystic fibrosis, sickle cell disease, pain management, and cell therapy programs. The company outlined expectations for five potential launches within five years and detailed development timelines for multiple clinical-stage candidates including exa-cel, VX-548, and VX-880. Key commercial initiatives included the targeted 2023 global launch of TRIKAFTA/KAFTRIO in younger CF patients and progress toward reaching all CF patients eligible for CFTR modulation therapy.
Yahsat FY 2022 Results Presentation 2023
earningsearnings
31 Pages
Al Yah Satellite Communications Company PJSC (Yahsat)
investor_presentation
13 Pages
earnings
43 Pages
Ryder System, Inc.
Stanbic Holdings 1H23 Financial Results Presentation
earningsearnings
28 Pages
Stanbic Holdings PLC